How do cancer patients respond to treatment? A simple blood test for TK1 might provide valuable information about progression and remission of cancer disease. TK1 as biomarker in cancer care can help clinicians make timely and informed decisions about ongoing treatments.
Thymidine Kinase 1 (TK1) is a sensitive cell proliferation and disruption biomarker that has been used to study hematological malignancies and solid tumors in vivo. Controlling and/or inhibiting cell proliferation is an important goal of cancer therapy. By determining the amounts of TK1 leaked into the blood, TK1 can serve as a cost-effective, powerful, and broad biomarker to monitor tumor cell progression, and/or remission and cell disruption as an effect of treatment. The clinical significance of TK1 has been shown in hematological malignancies, breast cancer, and other solid tumor diseases.
The development of anticancer therapies and tumor biomarkers is being rapidly advanced due to a greater understanding of the genetic and biological factors that stimulate and inhibit tumor growth. The rapid development of new drugs, such as those used in cancer immunotherapy, is offering new hope and possibilities in treatment of previously incurable malignancies. However, the very high cost of novel therapies, often in the range of hundreds of thousands of dollars for a single patient, plus the risk of side effects, is necessitating improved patient monitoring and selection. Thus, biomarkers will have an increasingly important role in future precision medicine.
TK1 has great potential as a biomarker for precision patient monitoring because it is a biomarker for the turnover of proliferating, or progression and/or regression of tumor cells. It could save considerable resources and avoid unnecessary side-effects in those less likely to benefit from a particular therapy. AroCell have developed a test to monitor the progression and remission of cancer. The easy to use AroCell TK 210 ELISA test measures TK1 in blood. It’s quick to perform and help clinicians make timely and informed decisions about ongoing treatments.